Experts in cutting-edge biology and medicine for diagnosis and therapy of human diseases

Our scientists understand precisely the genomic and molecular implications of innovative therapies and can quickly translate this knowledge to support our clients' advanced research.

At the forefront of the $50 billion revolution in Precision Medicine

Syreon is a leader in this exciting field where molecular sciences, biomarker-guided therapy and adaptive trials are key to speed and success.

International leaders in outcomes research health economics and policy development

Our experts are international leaders in health outcomes, economics and policy, developing advanced cost and utility models for global pharma and emerging biotech corporations.


End-to-end services

Syreon works with early-stage biotech companies and an elite portfolio of top-20 global pharma corporations to identify therapeutic needs, to evaluate new drug treatments and companion diagnostics, to evaluate costs and develop pricing strategies, to support market access, and to monitor effective clinical use and economic value in today's competitive health environment.

Global operations

Our head offices in North America and Europe coordinate an international network of expert research teams providing professional support to sponsors, investigators, providers, and payers. Our services through all phases of study planning, operation and analysis ensure safe, effective and value-driven clinical use of new drugs, diagnostics and medical devices.

Leading expertise

Our scientists are at the forefront of personalized therapeutics in a broad range of areas, from genomics and companion diagnostics to therapeutic trials, cellular replacement and stem cell therapeutics, health quality measurement, disease burden estimation, economic modeling and policy analysis in preparation for the revolution in valuation and pricing.

Our broad expertise

In precision medicine and real world research studies

Syreon excels not only in common therapeutic areas, but also in the advancing technologies of molecular sciences, stem cell transplantation and therapeutics, immune disease and immuno-oncology, and in the broader areas of organ failure, inflammatory disease and targeted therapy.

We complement our trials with companion studies to evaluate costs and develop pricing strategies, to support market access, and to monitor effective clinical use and economic value in today's competitive health environment. Some of our therapeutic areas include:

Our key therapeutic areas

  • Dermatology
  • Rheumatology
  • Skeletal diseases
  • Neurology
  • Psychiatry
  • Ophthalmology
  • Cardiology
  • Respirology
  • Hepatology
  • Gastroenterology
  • Nephrology
  • Endocrinology
  • Metabolism
  • Oncology
  • Infectious diseases
  • Immune diseases
  • Women's health
  • Transplantation


Chief Executive Officer   Paul A. Keown   MD, DSc, MBA
Professor of Medicine and Pathology. Molecular and clinical medicine and advisor to government, academia and industry.

Chief Executive Officer   Zoltan Kalo   MD, MSc, PhD
Professor of Health Economics. Economic analysis, strategic pricing and policy, advisor to government, academia and industry.

Medical Director   Zoltan Voko   MD, PhD, DSc
Professor of Health Economics. Epidemiology, statistics, national health policy and healthcare delivery.

Medical Director   Olaf Heisel   MD, PhD
Molecular and clinical medicine, clinical trial design, outcome analysis, pharmacovigilance and scientific reporting.

Medical Director   Ryan Sukhoo   MD
Late-phase clinical trials, health outcomes and patient-reported measures for longitudinal real-world research.

Director, Operations   Rohinish Gunadasa   BSc
Clinical trials operations, early-phase trials, health outcomes research, financial reporting and global operations management.

Director, Information Sciences   David Shilvock   BSc
Information and computing sciences, EDC and ePRO development, data exchange and international communications.

Director, Statistical Sciences   Hans Prestele   PhD
Statistical and data sciences, having served for over 20 years as Senior Director of these services for global pharma.

Research Director, US   Richard Howell   BSc
Product development, clinical research, market transition and global marketing for emerging and global pharma.

Research Director, EU   Marta Garcia   PhD
Early and late-phase clinical trials, regulatory affairs and product development throughout the EU.

Director, Regulatory Affairs   Jean Smart   MSc
Global regulatory policy development, clinical compliance / quality management, and advisor / Chair to ICH committees.

Client Liaison Officer   Tatiana Tkachenko  
Client liaison for early-phase clinical trials, health outcomes research and drug development in NA, EU, Asia and Eastern Europe.